Welcome to a ore Colorful World BD BD Horizon Brilliant Violet x 1, Lymph x 1, CD3+ CD8 PerCP-Cy5-5-A CD4+ 5 1
|
|
- さあしゃ ひきぎ
- 5 years ago
- Views:
Transcription
1 Brilliant Violet マルチカラー トレーニング キャンペーン BD Brilliant Violet 2 ( ) 1 ( ) P12 Brilliant Violet
2 Welcome to a ore Colorful World BD BD Horizon Brilliant Violet x 1, Lymph x 1, CD3+ CD8 PerCP-Cy5-5-A CD FSC-A 2 25 x 1, CD3 APC-H7-A CD4 Brilliant Violet 51-A CD25 Brilliant Violet 421-A CD25+++ CD25++ CD25 Brilliant Violet 421-A CD25+++Foxp3+ CD45RA FITC-A CD4 Brilliant Violet 51-A Foxp3 PE-A CD25 Brilliant Violet 421-A CD127 PE-CF594-A CD127 dim CD25 high CD25 Brilliant Violet 421-A -149 CD25 Brilliant Violet 421-A CD45RA- CD45RA CD45RA FITC-A 1 5 Count CCR7 PE-Cy7-A 1 5 BD Horizon Brilliant Violet Treg 9 PBC anti-human CD3-APC-H756275anti-human CD4-Brilliant Violet anti-human CD8-PerCP-Cy anti-human CD25-Brilliant Violet anti-human CD127-PE-CF anti-human CD45RA-FITC anti-human CD197 CCR7 -PE-Cy BD Transcription Buffer Set test / tests anti-human Foxp3-PE5682 CD3 CD4 CD4 T 2
3 BD TEL x 1, 25 2 Splenocyte x 1, 25 2 x 1, FSC-W 15 1 SSC-W 15 1 Singlet Singlet FSC-A x 1, FSC-H x 1, SSC-H x 1, x 1, CD3e- CD3e+ CD8a PE-A CD8a+ B22 PE-Cy7-A CD45R/B22+ NK , CD3e APC-Cy7-A 1 5-1, CD CD4 Alexa Fluor 488-A -1,45 B22-NK ,561 NK11 Brilliant Violet 421-A Ly-6G PE-CF594-A Ly-6G+Ly-6C LY-6G+ Ly-6G-Ly6-C Ly-6G+ CD11b APC-A CD11b+ -5, Ly-6C Ly-6G Brilliant Violet 51-A Ly-6C Ly-6G Brilliant Violet 51-A 2 BD Horizon Brilliant Violet TBNK 8 BALB/c ouse BD FcBlock553142anti-mouse CD3e-APC-Cy anti-mouse CD4-Alexafluor anti-mouse CD8a-PE anti-mouse NK1.1-Brilliant Violet anti-mouse CD45R/B22-PE-Cy anti-mouse Ly-6C/Ly-6G-Brilliant Violet anti-mouse Ly-6G-PE-CF anti-mouse CD11b-APC Cell Viability Solution
4 BD Horizon Brilliant Violet Dyes BD Horizon Brilliant Violet BD BV421 BV51 BV65 BV65 BV711 5 BV786 3PE T / PFA EDTA nm BD D Horizon V45 BD Horizon o i o BV BD Horizon o V5 BD Horizon BD Horizon BV51 BV65 BD Horizon BV65 BD Horizon BV711 BD Horizon BV Wavelength (nm) 4
5 Count Count Count Count Count CD25 Brilliant Violet 421-A CD25 FITC-A CD25 PE-A CD25 APC-A CD25 V45-A x 1, CD25++ CD x 1, x 1, x 1, x 1, CD25 Brilliant Violet 421-A CD25 FITC-A CD25 PE-A CD25 APC-A CD25 V45-A CD25 anti-human CD4-PerCP-Cy anti-human CD25 Brilliant Violet FITC 5699PE557138APC56987BD Horizon V CD4 BV421 BV65 BV BV51 BV65 BV65 APC AF7 BV711 AF7 PerCP-Cy 5.5 BD BD Brilliant Violet Web Page tech_cell@bd.com 1 * BV , / 5 BV / 5 BD FACSVerse BD LSRBD LSRFortessa BD FACSAria BD Influx BD FACSCanto BD FACSVerse BD LSRBD LSRFortessa BD FACSAria BD Influx BD FACSCanto BD FACSJazz BV / 2 BD LSRBD LSRFortessa BD FACSAria BD Influx BV / 2 BD LSRBD LSRFortessa BD FACSAria BD Influx BV / 5 BD LSRBD LSRFortessa BD FACSAria BD Influx BV / 6 BD LSRBD LSRFortessa BD FACSAria BD Influx * 5
6 Akt ps473, s V45 5 tests , Alkaline Phosphatase Annexin V B4-78 V45 1 tests , V45 5 tests , V5 5 tests , B7-H4 IH43 BV421 5 tests , Bcl-2 Bcl-2/1 V45 5 tests , Bcl-6, s K V45 5 tests , BrdU 3D4 V45 5 µg , Caspase-3, Active Form CD1d s 1B1 CD2 RPA-2.1 CD3 CD3e CD3 olecular Complex CD4, s C92-65 V45 5 tests , Cyno s UCHT1 SP C11 5A2 BV421 5 µg , BV51 5 µg ,* BV421 1 tests , BV tests , BV421 1 tests , BV tests , BV51 5 tests , PB 1 µg , V45 5 tests , V45 12 tests , V45 3 tests , V5 1 tests , V5 25 tests , BV421 5 tests , BV51 5 tests , BV65 5 tests , PB 1 µg , V45 12 tests , V45 3 tests , V5 1 tests , V5 25 tests , BV421 5 µg , BV51 5 µg , BV65 5 µg , BV711 5 µg , PB 1 µg , V45 1 µg , V45 25 ug , V5 1 µg , V5 25 ug , s 17A2 V45 5 µg , s RPA-T4 SK3 RPA-T4 L2 PB Pacific Blue * GK1.5 R4-5 BV421 1 tests , BV tests , BV51 1 tests , BV51 25 tests , BV65 1 tests , BV65 25 tests , PB 1 µg , V45 5 tests , V45 12 tests , V45 3 tests , V5 1 tests , V5 25 tests , BV51 5 tests , BV65 5 tests , V45 5 tests , V5 5 tests , BV421 5 µg , BV65 5 µg , BV711 5 µg , BV786 5 µg ,* BV51 5 µg , PB 1 µg , V45 1 µg , V45 25 ug , V5 1 µg , V5 25 ug , Rat OX-35 V45 5 µg , BV421 1 tests , UCHT2 BV711 5 tests , CD5 V45 5 tests , BV421 5 µg , s BV51 5 µg , V45 5 µg , CD7 -T71 BV421 1 tests , BV421 1 tests , BV tests , BV51 5 tests ,* RPA-T8 PB 1 µg , V45 12 tests , V45 3 tests , CD8 V5 1 tests , V5 25 tests , RPA-T8 V45 5 tests , SK1 V5 5 tests , Rhe, SK1 V5 5 tests , BV51 5 µg , BV65 5 µg , BV711 5 µg , BV786 5 µg ,* CD8a s PB 1 µg , V45 1 µg , V45 25 ug , V5 1 µg , V5 25 ug , Rat OX-8 V45 5 µg , CD9 -L13 V45 5 tests , BV421 1 tests , CD1 HI1a BV51 5 tests , BV65 1 tests , CD11a s 2D7 BV421 5 µg , BV421 5 µg , BV51 5 µg , BV65 5 µg ,* BV711 5 µg , s 1/7 CD11b V45 1 µg , V45 25 ug , V5 1 µg , V5 25 ug , Rat WT.5 V45 5 µg , BV421 1 tests , BV51 5 tests , BV65 1 tests , CD11b/AC-1 ICRF44 BV65 25 tests , PB 1 µg , V45 12 tests , V45 3 tests , BV421 1 tests , B-ly6 BV711 5 tests , V45 12 tests , V45 3 tests , CD11c BV421 5 µg , BV51 5 µg , s HL3 BV65 5 µg ,* BV711 5 µg , V45 5 µg , CD13 W15 BV421 1 tests , BV51 5 tests , V45 12 tests , ΦP9 V45 3 tests , V5 1 tests , V5 1 tests , V5 25 tests , CD14 5E2 V45 5 tests , Cyno Cyno, 5E2 PB 1 µg , Bab, Dog s rmc5-3 V45 5 µg , 6
7 CD15 CD16 W6D3 HI98 3G8 BV65 1 tests , BV711 5 tests , V45 5 tests , V5 5 tests , BV421 1 tests , BV tests , BV711 5 tests , PB 1 µg , V45 12 tests , V45 3 tests , V5 25 tests , V5 1 tests , V45 5 tests , BV65 1 tests ,* BV65 25 tests ,* B73.1 V45 5 tests , CD16/CD32 s 2.4G2 BV421 5 µg , V45 5 µg , CD18 Cyno, Pig, 6.7 BV421 1 tests , Rab s C71/16 BV421 5 µg , BV421 1 tests , BV tests , HIB19 V45 12 tests , V45 3 tests , V5 1 tests , V5 25 tests , BV51 1 tests , BV51 25 tests , BV65 1 tests , BV65 25 tests , BV65 1 tests , SJ25C1 CD19 BV65 25 tests , BV711 1 tests , BV tests , BV786 1 tests ,* BV tests ,* BV421 5 µg , BV51 5 µg , BV65 5 µg ,* s 1D3 BV711 5 µg , BV786 5 µg ,* V45 1 µg , V45 25 ug , 2H7 BV421 1 tests , L27 V45 5 tests , CD2 2H7 BV711 5 tests , L27 V45 5 tests , V45 5 tests , Cyno, Bab, Pig V45 5 tests , CD21 B-ly4 BV421 1 tests , Cyno, BV711 5 tests , Bab, Pig BV421 5 µg , CD21/CD35 s 7G6 BV51 5 µg ,* BV65 5 µg ,* -L233 BV421 1 tests , CD23 BV421 5 µg , s B3B4 BV51 5 µg , BV421 1 tests , L5 BV51 5 tests , CD24 BV65 1 tests , BV421 5 µg , s 1/69 BV51 5 µg ,* BV65 5 µg ,* BV421 1 tests , -A251 BV tests , V45 12 tests , V45 3 tests , BV65 1 tests , CD25 2A3 BV65 25 tests , BV711 5 tests , BV421 5 µg , s PC61 BV51 5 µg ,* BV65 5 µg ,* V45 5 µg , BV421 1 tests , BV tests , V45 12 tests , V45 3 tests , -T271 V5 1 tests , V5 25 tests , V45 5 tests , CD27 BV51 25 tests , BV51 1 tests , BV65 1 tests , BV65 25 tests , L128 BV65 1 tests , BV65 25 tests , BV711 5 tests , BV786 1 tests ,* BV tests ,* s LG.3A1 V45 5 µg , BV421 1 tests , BV51 5 tests , BV65 1 tests , BV65 25 tests , CD28.2 CD28 BV711 5 tests , V45 5 tests , V45 5 tests , s BV421 5 µg , CD29 s, Rat Ha2/5 V45 5 µg , CD3 BerH8 BV421 1 tests , CD31 W59 BV65 5 tests , V45 5 tests , s EC 13.3 BV421 5 µg ,* BV51 5 µg , CD32 s 2.4G2 BV65 5 µg ,* BV421 5 tests , CD33 W53 BV711 5 tests , V45 5 tests , CD BV421 1 tests , s RA34 BV421 5 µg , CD36 CB38 V45 5 tests , CD37 -B371 V45 5 tests , HIT2 BV421 1 tests , BV tests , BV65 1 tests , HB7 CD38 BV65 25 tests , HIT2 V45 5 tests , s 9/CD38 also known as Ab9 BV421 5 µg , CD4 5C3 V45 5 tests , s BV421 5 µg , CD41 s WReg3 BV421 5 µg , CD41a HIP8 V45 5 tests , 1G1 BV421 1 tests , CD43 CD44 s S7 BV65 1 µg G44-26 s I7 BV421 1 tests , BV51 5 tests , V45 5 tests , BV51 5 µg , V45 1 µg , V45 25 µg , V5 1 µg , V5 25 µg , 7
8 CD45 BV51 1 tests , V45 12 tests , HI3 V45 3 tests , V5 1 tests , V5 25 tests , s 3-F11 V45 5 µg , V5 5 µg , Rat OX-1 V45 5 µg , Rhe, V45 5 tests , D V5 5 tests , CD45.1 s A2 BV65 5 µg ,* V45 5 µg , BV421 5 µg , CD45.2 s 14 V45 5 µg , V5 1 µg , V5 25 µg , BV51 5 µg ,* CD45R s RA3-6B2 V45 1 µg , V45 25 µg , BV421 5 µg , CD45R/B22 s RA3-6B2 PB 1 µg , V5 1 µg , V5 25 µg , BV421 5 tests , BV51 5 tests , HI1 BV65 5 tests , V45 12 tests , CD45RA V45 3 tests , V5 5 tests , 5H9 V45 5 tests , Rat OX-33 V45 5 µg , CD45RB s 16A BV421 5 µg , BV421 1 tests , CD45RO UCHL1 BV65 25 tests , BV65 1 tests , CD47 B6H12 V45 5 tests , CD48 TÜ145 BV421 1 tests , s H48-1 BV421 5 µg , CD49b s DX5 BV421 5 µg , V45 5 µg , CD49d Cyno, Bab, Dog, Bov 9F1 BV711 5 tests , CD49f GoH3 BV421 1 tests , BV tests , BV421 1 tests , BV tests , BV51 5 tests ,* NCA16.2 BV65 25 tests , CD56 BV65 1 tests , BV711 5 tests ,* B159 V45 12 tests , V45 3 tests , CD59 Rat TH9 V45 5 µg , CD61 s, Rat 2C9.G2 BV421 5 µg , BV65 1 tests , DREG-56 BV65 25 tests , V45 12 tests , CD62L V45 3 tests , BV421 5 µg , s EL-14 BV51 5 µg , BV65 5 µg ,* V45 5 µg , CD63 H5C6 V45 5 tests , CD BV421 5 tests , V45 5 tests , CD66 B1.1/CD66 BV421 1 tests , CD66b G1F5 BV421 1 tests ,* V45 5 tests , CD69 FN5 BV421 1 tests , BV65 1 tests , V45 5 tests , BV421 5 tests , BV421 5 µg , s H1.2F3 BV51 5 µg , V45 5 µg , CD7 s FR7 BV421 5 µg , BV421 5 µg , CD71 s C2 BV51 5 µg , BV65 5 µg , BV421 1 tests , CD73 AD2 BV tests , V45 5 tests , s TY/23 V45 5 µg , CD79a H47 BV421 5 tests , BV51 5 tests , L37.4 V45 12 tests , CD8 V45 3 tests , s 16-1A1 BV421 5 µg , V45 5 µg , HB15e BV421 5 tests , CD83 BV51 5 µg ,* s ichel-19 BV65 5 µg ,* BV711 5 µg ,* BV421 1 tests , BV tests , V45 12 tests , 2331 FUN-1 V45 3 tests , CD86 BV711 5 tests , BV51 5 µg , s GL1 BV65 5 µg ,* V45 1 µg , V45 25 µg , BV51 5 tests , BV65 1 tests , BV65 25 tests , CD9 5E1 Cyno, Bab, Pig, BV421 1 tests , Dog CD9.1 s, Rat OX-7 V45 5 µg , BV65 5 µg ,* CD9.2 s V45 5 µg , V5 5 µg , BV421 1 tests , V45 5 tests , BV421 5 tests , CD95 Cyno, Bab, Pig, Dog DX2 BV711 5 tests , V45 5 tests , s Jo2 BV421 5 µg , CD96 6F9 BV711 5 tests , Ber-ACT8 BV711 5 tests ,* CD13 BV421 5 µg , s 29 BV51 5 µg , BV51 5 tests ,* CD BV65 5 tests , V45 5 tests , CD16 s 429 VCA.A V45 5 µg , BV421 5 tests , CD17a H4A3 BV51 5 tests , V45 5 tests , s 1D4B V45 5 µg , PB Pacific Blue *
9 BV421 1 tests , YB5.B8 BV tests , 14D2 BV65 5 tests , CD117 BV421 5 µg , s 2B8 BV65 5 µg , BV711 5 µg , V45 5 µg , CD121b s 4 BV421 5 µg , BV421 5 tests , ik-β3 CD122 BV51 5 tests , s T-Beta 1 BV421 5 µg ,* BV421 5 tests , CD123 9F5 BV51 5 tests , BV711 5 tests , BV421 1 tests , BV tests , BV51 5 tests , BV65 5 tests , HIL-7R-21 BV65 5 tests , CD127 BV711 5 tests , BV786 5 tests ,* V45 5 tests , s SB/199 BV421 5 µg , SB/199q V45 5 µg , CD132 AG184 BV421 5 tests , BV711 5 tests , CD135 s A2F1.1 BV421 5 µg , BV421 5 tests , I15 BV51 5 tests , BV711 5 tests , CD138 V45 5 tests , BV421 5 µg , s BV51 5 µg , BV65 5 µg , BV711 5 µg , CD14a αr1 BV421 5 tests , s APA5 BV421 5 µg , CD141 1A4 BV711 5 tests , CD H1 V45 5 tests , s 11D4.1 BV421 5 µg , BV711 5 tests , P1H12 CD146 V45 5 tests , s E-9F1 V45 5 µg , CD147 HI6 BV421 5 tests , s RL73 BV421 5 µg , CD15 A12 BV421 5 tests , s Q38-48 BV421 5 µg , CD152 BNI3 BV421 5 tests , CD158a HP-3E4 BV711 5 tests , CD161 DX12 BV421 5 tests , CD162 s 2PH1 BV421 5 µg , CD163 GHI/61 BV421 5 tests , CD166 3A6 BV421 5 tests , BV421 5 tests , CD183 1C6/CXCR3 BV711 5 tests , s CXCR3-173 BV421 5 µg , 12G5 BV421 5 tests , CD184 BV421 5 µg , s 2B11/CXCR4 V45 5 µg , CD193 5E8 BV421 5 tests , BV51 5 tests , BV421 5 tests , CD194 1G1 BV51 5 tests , BV65 5 tests , V45 5 µg , CD195 2D7/CCR5 BV421 5 tests , V45 5 tests , CD196 11A9 BV421 5 tests , BV65 5 tests , BV421 5 tests , 1553 V45 12 tests , CD197 V45 3 tests , s 4B12 BV421 5 µg , V45 1 µg , CD2 RC OX-14 BV65 5 tests , V45 5 tests , CD29 DCN46 V45 5 tests , CD221 1H7 BV421 5 tests , CD223 s C9B7W BV711 5 µg ,* CD235a GA-R2 HIR2 BV421 5 tests , CD271 C BV421 5 tests , V45 5 tests , CD276 s IH32 BV421 5 µg , CD278 B56 BV421 5 tests , DX29 BV421 5 tests , BV421 5 tests , EH12.1 CD279 BV51 5 tests , s J43 BV421 5 µg , CD294 B16 BV421 5 tests , V45 5 µg , CD314 s CX5 BV421 5 µg , BV65 5 tests , 9E2/Nkp46 BV711 5 tests , CD335 NKp46 BV786 5 tests ,* BV421 5 µg , s 29A1.4 V45 1 µg , V45 25 ug , CD338 5D3 BV421 5 tests , BV421 5 tests , RF8B2 CXCR5 BV51 5 tests , s 2G8 BV421 5 µg , ERK1/2 pt22/py24, s, Rat 2A FLK-1 s Avas 12alpha1 FoxP3 s 259D/C7 F23 PB 5 tests , BV421 5 tests , BV421 5 µg , V45 5 µg , V45 12 tests , V45 3 tests , V45 1 tests , BV421 5 µg , V45 5 µg , G-CSF BV D2-21C11 BV421 5 tests , Granzyme B GB11 V45 5 tests , H-2K b s AF BV421 5 µg , Histone H3 ps28 s HTA28 V45 5 tests , HLA-A,B,C G V45 5 tests , HLA-A2 BB7.2 V45 5 tests , BV421 1 tests , BV tests , BV51 5 tests , V45 5 tests , HLA-DR G46-6 V5 1 tests , V5 25 tests , I-A/I-E s 5/ BV65 25 tests , BV65 1 tests , BV421 5 µg , V5 5 µg , I-A b s AF BV421 5 µg , IFN-α2b 7N4-1 V45 5 tests , BV421 5 tests , BV65 5 tests , IFN-γ B27 V45 12 tests , V45 3 tests , V5 5 tests , s XG1.2 V45 5 µg , BV421 5 tests , G2-193 Ig, κ Light Chain V45 5 tests , s V45 5 µg , BV421 5 tests , IA6-2 BV51 5 tests , V45 5 tests , IgD V5 5 tests , BV51 5 µg ,* s 11-26c.2a BV65 5 µg ,* V45 5 µg , IgE s R35-72 BV51 5 µg ,* IgG G BV421 5 tests , V45 5 tests , 9
10 IgG1 s A85-1 Ig G2-127 s R6-6.2 BV421 5 µg , V45 5 µg , BV421 5 tests , BV51 5 tests ,* BV65 5 tests ,* V45 5 tests , BV421 5 µg , BV51 5 µg ,* V45 5 µg , IL-1 s JES5-16E3 V45 5 µg , IL-12 p4/p7 C11.5 V45 5 tests , s C15.6 V45 5 µg , IL-13 JES1-5A2 V45 5 tests , BV421 5 tests , N IL-17A V45 5 tests , s TC11-18H1 V45 5 µg , IL-17F O V45 1 tests , V45 25 tests , BV421 5 tests , BV51 5 tests ,* IL-2 V45 5 tests , s JES6-5H4 BV421 5 µg ,* V45 5 µg , IL-4 8D4-8 BV421 5 tests , V45 5 tests , s 11B11 BV421 5 µg , V45 5 µg , IL-6 Q2-13A5 V45 5 tests , s P5-2F3 V45 5 µg , ILT7 CD85g 17G1.2 BV421 5 tests , Invariant NK T-Cell 6B11 BV51 5 tests ,* BV711 5 tests ,* Ki-67 B56 V45 5 tests , KLRG1 s 2F1 BV421 5 µg , V45 5 µg , Lgr5 8F2 BV421 5 tests , Light Chain, λ JDC-12 BV421 5 tests , V45 5 tests , LPA-1 s DATK32 BV421 5 µg , Ly-49AB6 s A1 V45 5 µg , BV421 5 µg , Ly-6A/E s D7 V45 5 µg , V5 1 µg , V5 25 ug , BV421 5 µg , Ly-6C s AL-21 BV65 5 µg ,* V45 5 µg , BV65 5 µg , LY-6G s 1A8 V45 5 µg , BV421 5 µg , BV421 5 µg , Ly-6G and Ly-6C s RB6-8C5 BV51 5 µg , V45 1 µg , V45 25 µg , IP-1β D BV421 5 tests , V45 5 tests , Nestin Rat 25/NESTIN V45 5 tests , BV421 5 µg , NK-1.1 s PK136 BV51 5 µg , BV65 5 µg ,* V45 5 µg , Nkp46 9E2/Nkp46 V45 5 tests , Oct- 2, s 9A2 BV421 5 tests ,* p38 APK pt18/py182, s, Rat 36/p38 pt18/py182 PB 5 tests , Pax-5, s 1H9 BV51 5 tests , RORγt s Q BV421 5 µg , S6 ps235/ps236 N7-548 V45 5 tests , Siglec-F s E5-244 BV421 5 µg , Sox2, s O3-678 V45 5 tests , SSEA-1 s C48 BV421 5 tests , V45 5 tests , SSEA-3 C-631 also known as C631 BV421 5 tests , SSEA-4 C813-7 V45 5 tests , Stat1 py71, s 14/P-STAT1 PB 5 tests , Stat3 py75, s 4/P-STAT3 PB 5 tests , Stat5 py694 47/Stat5 py694 PB 5 tests , Stat6 py641 18/P-Stat6 V45 5 tests , Streptavidin BV421 1 µg BV51 1 µg BV65 1 µg BV711 1 µg V45 1 µg , V5 1 µg , T-bet, s O4-46 V45 5 tests , BV421 5 µg , TCR β Chain s H BV51 5 µg ,* BV65 5 µg , V45 5 µg , TCR γδ B1 BV421 5 µg , s GL3 BV421 5 µg , TCR Vα 2 s B2.1 BV421 5 µg , V45 5 µg , TCR Vβ 13 s R12-3 V45 5 µg , TER-119/ Erythroid cell s TER-119 V45 5 µg , V5 5 µg , TGF-β1 TW4-9E7 BV421 5 tests ,* BV421 5 tests , ab11 TNF V45 5 tests , s P6-XT22 V45 5 µg , BV421 5 tests , TRA-1-6 Antigen TRA-1-6 V45 5 tests , PB Pacific Blue *
11 BV421 5 µg , V45 1 µg , Ham IgG1, κ A19-3 BV51 5 µg , BV65 5 µg , BV711 5 µg , V45 1 µg , BV421 5 µg , Ham IgG1, λ1 G BV51 5 µg , BV711 5 µg , BV65 5 µg , BV421 5 µg , PB 1 µg , B81-3 Ham IgG2, κ V45 1 µg , V5 1 µg , Ha4/8 BV421 5 µg , Ham IgG2, λ1 Ha4/8 BV51 5 µg , BV65 5 µg , Ham Ig, λ1 G235-1 V45 1 µg , s Ig, κ BV421 5 µg , s IgA, κ V45 1 µg , BV421 5 µg , V45 1 µg , V5 1 µg , BV51 5 µg , X4 BV65 5 µg , s IgG1, κ BV65 5 µg , BV711 5 µg , BV786 5 µg , OPC-21 PB 1 µg , V45 1 µg , OPC-173 V45 1 µg , BV421 5 µg , s IgG2a, κ BV51 5 µg , G PB 1 µg , V45 1 µg , V5 1 µg , BV421 5 µg , BV51 5 µg , s IgG2b, κ V45 1 µg , V5 1 µg , BV711 5 µg , s IgG3, κ J66 V45 1 µg , BV421 5 µg , V45 1 µg , s Ig, κ G V5 1 µg , BV711 5 µg , BV51 5 µg , BV421 5 µg , BV65 5 µg , Rat IgG1, κ R3-34 BV711 5 µg , BV51 5 µg , V45 1 µg , BV421 5 µg , Rat IgG1, λ A11-1 BV51 5 µg , BV65 5 µg , V45 1 µg , BV421 5 µg , BV51 5 µg , BV65 5 µg , BV65 5 µg , Rat IgG2a, κ R35-95 BV711 5 µg , BV786 5 µg , PB 1 µg , V45 1 µg , V5 1 µg , BV421 5 µg , Rat IgG2a, λ B39-4 BV65 5 µg , V45 1 µg , Rat IgG2b, κ R35-38 BV421 5 µg , BV786 5 µg , A95-1 V45 1 µg , V5 1 µg , BV51 5 µg , Rat IgG2b, κ BV65 5 µg , R35-38 BV65 5 µg , BV711 5 µg , V45 1 µg , BV421 5 µg , Rat Ig, κ R4-22 BV51 5 µg , BV65 5 µg , BV711 5 µg , 7-AAD Staining Solution 2. ml , Fixable Viability Stain 45.1 mg , Violet Proliferation Dye mg , Transcription Factor Buffer Set 1 tests , 25 tests , man FoxP3 Buffer Set 1 tests , ouse Foxp3 Buffer Set 1 tests , Foxp3 BD Cytofix / Cytoperm Fixation / Permeabilization Solution Kit 25 tests , BD Cytofix / Cytoperm Plus Fixation / Permeabilization Solution Kit with BD GolgiStop 25 tests , Breferdin A BD Cytofix / Cytoperm Plus Fixation / Permeabilization Solution Kit with BD GolgiPlug 25 tests , onencin BD Cytofix / Cytoperm Fixation / Permeabilization Solution 125 ml , BD Cytofix Fixation Buffer 1 ml , BD Perm / Wash Perm/Wash Buffer 1 ml , Stain Buffer(FBS) 5 ml , Stain Buffer(BSA) 5 ml , BD PharmLyse Lysis Buffer(1X concentrate) 1 ml , 11
12 Brilliant Violet マルチカラー トレーニングキャンペーン BV 1 tech_cell@bd.com TEL Brilliant Violet T Sirigen Group Ltd. Cy T Amersham Bioscience Corp. Alexa Fluor olecular Probe Inc. BD BD Becton, Dickinson and Company 213 BD R
2 A2B, 0/A2B IgM AF647 0 T ,000 C3/AFP IgG Annexin V AF488 0 T ,000 PE 0 T ,000 APC 2 T ,000 FITC 2 T ,000 PE 2 T 60
BD Biosciences * 2 A2B, 0/A2B IgM AF647 0 T 63776 4,000 C3/AFP IgG Annexin V AF488 0 T 6306 42,000 PE 0 T 63002 40,000 APC 2 T 602 20,000 FITC 2 T 6093 8,000 PE 2 T 60930 2,000 Alphafetoprotein 0 T 643
More informationBE0005 TS-1/ InVivoMab anti-human LFA-1α (CD11a) mouse IgG , ,000 BE0005 TS-1/ InVivoMab anti-human LFA-1α (CD11a) mous
Bio X Cell 社価格表 (2018 年 4 月 ) < 株式会社シン コーポレーション > Bio X Cell 社価格表 (2018 年 4 月 ) ご注文ごとに別途取扱手数料 (2( 万円 税別 ) を申し受けます 大学向け価格でのご購入には アカデミックプライス適用申込書のご提出が必須となります 品番クローン品名イソタイプ 容量 (mg) 大学向希望小売価格 ( 円 ) 税別 希望小売価格
More informationPowerPoint プレゼンテーション
Isotype 略語紹介 AF 488 Alexa Fluor 488 AF 594 Alexa Fluor 594 AF 647 Alexa Fluor 647 AF 700 Alexa Fluor 700 BV 421 Brilliant Violet 421 BV 510 Brilliant Violet 510 BV 570 Brilliant Violet 570 BV 605 Brilliant
More informationMACSスターティングキットの選択方法
ミルテニーバイオテク株式会社 初めての MACS スターティングキットの選択方法 初めて MACS テクノロジーによる細胞分離をお試しになる場合は スターティングキットが最適です スターティングキットは 細胞分離に 必要な機器と試薬がセットなっており 個々にご購入いただくよりも安価でご利 いただけます 多様な実験系のために 13 種類のスター ティングキットをご 意しています 選択方法に従って 最適なキットをお選びください
More information<8DD AA97A3834C B BF8A69838A C8EA E786C7378>
ST-01738 ErythroClear Red Blood Cell Depletion Reagent kit 臍帯血 2 ml 用 17,000 13,600 ST-01739 ErythroClear Red Blood Cell Depletion kit 臍帯血 2 ml 用 475,000 380,000 ST-07801 Lymphoprep 250 ml 17,000 13,600
More informationAmnis TM CellStream TM CellStream TM
Amnis TM CellStream TM CellStream TM Amnis TM CellStream TM Amnis TM CCD FITC PE 5 96 7 CFR Part FDA TM CellStream Luminex Time Delay Integration TDI CellStream. 7... CCD CellStream Amnis CCD CellStream
More information第14〜15回 T細胞を介する免疫系.pptx
MBL CD8 CD4 8.1 8.2 5.20 8.3 8.4 8.5 8.6 8.7 8.8 8.9 8.10 8.18 B7 CD28 CD28 B7 CD28 8.13 2.22 NK Toll(TLR) LBP! LPS dsrna ssrna TLR1/2/6! TLR4 TLR5 TLR3 TLR7/9 CD14! JNK/p38! MyD88! IRAK! TRAF! NFκB! TNF-α
More information170920_BioXCell社カタログ改訂2【9校】.indd
BULK ANTIBODIES for in vivo RESEARCH Bio X Cell in vivo InVivoPlus 0.001 EU/ug 95 5 FACS ELISA 4-1BB CD137 Mouse LOB12.3 Rat IgG1 4-1BB activation BP0169 CD3 ε Mouse 145-2C11 Armenian Hamster IgG1 DP,
More informationCytoFLEX Family Brochure
CytoFLEX Family CytoFLEX CytoFLEX CytoFLEX CytoFLEX CytoFLEX 1 CytoFLEX S 1 CytoFLEX LX 21 2 EVERY ERY Event Matters ters CytoFLEX 1 T T IR CD8 IR CytoFLEX / Karen Hogg, PhD, Bioscience Technology Facility,
More information2001 Mg-Zn-Y LPSO(Long Period Stacking Order) Mg,,,. LPSO ( ), Mg, Zn,Y. Mg Zn, Y fcc( ) L1 2. LPSO Mg,., Mg L1 2, Zn,Y,, Y.,, Zn, Y Mg. Zn,Y., 926, 1
Mg-LPSO 2566 2016 3 2001 Mg-Zn-Y LPSO(Long Period Stacking Order) Mg,,,. LPSO ( ), Mg, Zn,Y. Mg Zn, Y fcc( ) L1 2. LPSO Mg,., Mg L1 2, Zn,Y,, Y.,, Zn, Y Mg. Zn,Y., 926, 1 1,.,,., 1 C 8, 2 A 9.., Zn,Y,.
More informationqxd
BD Pharmingen TM BrdU Flow Kit FITC BrdU Flow Kit 559619 50 557891 4 50 APC BrdU Flow Kit 552598 50 557892 4 50 2005 Becton, Dickinson and Company. All rights reserved. BD Biosciences Becton, Dickinson
More informationThe Molecular Probes Handbook, 11th Edition 3, The Molecular Probes Handbook www. thermofisher.com/handbook Fluorescen
The Molecular Probes Handbook, 11th Edition 3, The Molecular Probes Handbook www. thermofisher.com/handbook www.thermofisher.com/antibodies Fluorescence SpectraViewer 14 www.thermofisher.com/spectraviewer
More informationB Violet Laser Tools(JPN) indd
Molecular Probes CD8 Zenon Pacific Orange Qdot 655-CD3 (655/2) : Pacific Blue Pacific Orange Qdot Pacific Blue Pacific Orange Pacific Blue dye 455 nm Pacific Orange dye 551 nm 1 1 Pacific Blue Pacific
More informationqxd
BD FACS TM Review Vol.7 BD FACSAria TM BD FACSAria FACS HLA-FACS Key words: HLA FACS 1988 Eliane Glukmann Fanconi 1 5 10% 30% mixed chimerism HLA human leukocyte antigen HLAFACS fluorescence activated
More informationDynalTransplantDiagnostic.indd
2011 1 SeCore HLA SBT 1 2 AllSet + Gold SSP HLA 7 3 SSP UniTray HLA 11 4 27 5 32 ii 1 SeCore HLA SBT SeCore 2 SeCore HLA SBT SeCore 3 SeCore 4 HLA-I 5 HLA-II 5 utype 5 GSSP 6 1 SeCore HLA SBT Sequencing
More information() () () () () 175 () Tel Fax
JPCA-PE04-02-01-02-01S JPCA PE04-02-01-02-01S 2005 () () () () () 175 () 167-0042 3122 2 Tel 03-5310-2020Fax 03-5310-2021e-mailstd@jpca.org Detail Specification for PT Optical Module 1 PT PT 12 Optoelectronic
More information免疫学研究のための製品群
ver.1.4 The path to new discoveries From basic to clinical research in immunology Good research starts with happy cells. gentlemacs TM Octo Dissociator with Heaters TM Whole Blood MicroBeads 37 RNA Option
More informationエピトープタグ抗体製品リスト PM020 Anti-DDDDK-tag pab Polyclonal Rabbit Ig (aff.) WB, IP, IC 100 ml 15,000 PM020-7 Anti-DDDDK-tag pab HRP-DirecT Polyclonal Rabbit I
(kda) 150 100 DDDDK-tagged protein 75 50 37 IgG Heavy chain 25 20 IgG Light chain Sample: N-terminal DDDDK-tagged β-gal protein transfectant μ μ μ http://ruo.mbl.co.jp/ エピトープタグ抗体製品リスト PM020 Anti-DDDDK-tag
More informationThe Molecular Probes Handbook, 11th Edition 3, The Molecular Probes Handbook Flu
Molecular Probes Molecular Probes The Molecular Probes Handbook, 11th Edition 3, The Molecular Probes Handbook www.lifetechnologies.com/handbook www.lifetechnologies.com/antibodies Fluorescence SpectraViewer
More information( )
18 10 01 ( ) 1 2018 4 1.1 2018............................... 4 1.2 2018......................... 5 2 2017 7 2.1 2017............................... 7 2.2 2017......................... 8 3 2016 9 3.1 2016...............................
More informationx V x x V x, x V x = x + = x +(x+x )=(x +x)+x = +x = x x = x x = x =x =(+)x =x +x = x +x x = x ( )x = x =x =(+( ))x =x +( )x = x +( )x ( )x = x x x R
V (I) () (4) (II) () (4) V K vector space V vector K scalor K C K R (I) x, y V x + y V () (x + y)+z = x +(y + z) (2) x + y = y + x (3) V x V x + = x (4) x V x + x = x V x x (II) x V, α K αx V () (α + β)x
More information0 (18) /12/13 (19) n Z (n Z ) 5 30 (5 30 ) (mod 5) (20) ( ) (12, 8) = 4
0 http://homepage3.nifty.com/yakuikei (18) 1 99 3 2014/12/13 (19) 1 100 3 n Z (n Z ) 5 30 (5 30 ) 37 22 (mod 5) (20) 201 300 3 (37 22 5 ) (12, 8) = 4 (21) 16! 2 (12 8 4) (22) (3 n )! 3 (23) 100! 0 1 (1)
More information1/68 A. 電気所 ( 発電所, 変電所, 配電塔 ) における変圧器の空き容量一覧 平成 31 年 3 月 6 日現在 < 留意事項 > (1) 空容量は目安であり 系統接続の前には 接続検討のお申込みによる詳細検討が必要となります その結果 空容量が変更となる場合があります (2) 特に記載
1/68 A. 電気所 ( 発電所, 変電所, 配電塔 ) における変圧器の空き容量一覧 平成 31 年 3 月 6 日現在 < 留意事項 > (1) 空容量は目安であり 系統接続の前には 接続検討のお申込みによる詳細検討が必要となります その結果 空容量が変更となる場合があります (2) 特に記載のない限り 熱容量を考慮した空き容量を記載しております その他の要因 ( 電圧や系統安定度など ) で連系制約が発生する場合があります
More informationx, y x 3 y xy 3 x 2 y + xy 2 x 3 + y 3 = x 3 y xy 3 x 2 y + xy 2 x 3 + y 3 = 15 xy (x y) (x + y) xy (x y) (x y) ( x 2 + xy + y 2) = 15 (x y)
x, y x 3 y xy 3 x 2 y + xy 2 x 3 + y 3 = 15 1 1977 x 3 y xy 3 x 2 y + xy 2 x 3 + y 3 = 15 xy (x y) (x + y) xy (x y) (x y) ( x 2 + xy + y 2) = 15 (x y) ( x 2 y + xy 2 x 2 2xy y 2) = 15 (x y) (x + y) (xy
More information(1.2) T D = 0 T = D = 30 kn 1.2 (1.4) 2F W = 0 F = W/2 = 300 kn/2 = 150 kn 1.3 (1.9) R = W 1 + W 2 = = 1100 N. (1.9) W 2 b W 1 a = 0
1 1 1.1 1.) T D = T = D = kn 1. 1.4) F W = F = W/ = kn/ = 15 kn 1. 1.9) R = W 1 + W = 6 + 5 = 11 N. 1.9) W b W 1 a = a = W /W 1 )b = 5/6) = 5 cm 1.4 AB AC P 1, P x, y x, y y x 1.4.) P sin 6 + P 1 sin 45
More information[RP13]シリーズカタログ
131520 : : : 2AAWG#24 : 2AAWG#22 1315 : AC30VDC42V 20 : AC100VDC140V 1. 1315 : 15m 20 : 30m DC1A -10 ~ +60-10 ~ +60 2. 1000M DC250V 3. AC300V1 4. 10s 10~55Hz/0.75mm 32 5. 10s 490m/s 2 11ms33 6. 7. 1315
More informationiii 1 1 1 1................................ 1 2.......................... 3 3.............................. 5 4................................ 7 5................................ 9 6............................
More informationIMO 1 n, 21n n (x + 2x 1) + (x 2x 1) = A, x, (a) A = 2, (b) A = 1, (c) A = 2?, 3 a, b, c cos x a cos 2 x + b cos x + c = 0 cos 2x a
1 40 (1959 1999 ) (IMO) 41 (2000 ) WEB 1 1959 1 IMO 1 n, 21n + 4 13n + 3 2 (x + 2x 1) + (x 2x 1) = A, x, (a) A = 2, (b) A = 1, (c) A = 2?, 3 a, b, c cos x a cos 2 x + b cos x + c = 0 cos 2x a = 4, b =
More information1990 IMO 1990/1/15 1:00-4:00 1 N N N 1, N 1 N 2, N 2 N 3 N 3 2 x x + 52 = 3 x x , A, B, C 3,, A B, C 2,,,, 7, A, B, C
0 9 (1990 1999 ) 10 (2000 ) 1900 1994 1995 1999 2 SAT ACT 1 1990 IMO 1990/1/15 1:00-4:00 1 N 1990 9 N N 1, N 1 N 2, N 2 N 3 N 3 2 x 2 + 25x + 52 = 3 x 2 + 25x + 80 3 2, 3 0 4 A, B, C 3,, A B, C 2,,,, 7,
More information第86回日本感染症学会総会学術集会後抄録(I)
κ κ κ κ κ κ μ μ β β β γ α α β β γ α β α α α γ α β β γ μ β β μ μ α ββ β β β β β β β β β β β β β β β β β β γ β μ μ μ μμ μ μ μ μ β β μ μ μ μ μ μ μ μ μ μ μ μ μ μ β
More informationlinearal1.dvi
19 4 30 I 1 1 11 1 12 2 13 3 131 3 132 4 133 5 134 6 14 7 2 9 21 9 211 9 212 10 213 13 214 14 22 15 221 15 222 16 223 17 224 20 3 21 31 21 32 21 33 22 34 23 341 23 342 24 343 27 344 29 35 31 351 31 352
More information新たな基礎年金制度の構築に向けて
[ ] 1 1 4 60 1 ( 1 ) 1 1 1 4 1 1 1 1 1 4 1 2 1 1 1 ( ) 2 1 1 1 1 1 1 1996 1 3 4.3(2) 1997 1 65 1 1 2 1/3 ( )2/3 1 1/3 ( ) 1 1 2 3 2 4 6 2.1 1 2 1 ( ) 13 1 1 1 1 2 2 ( ) ( ) 1 ( ) 60 1 1 2.2 (1) (3) ( 9
More information‚å™J‚å−w“LŁñfi~P01†`08
156 2003 2 3 4 5 6 7 8 9 c f c a g 10 d c d 11 e a d 12 a g e 13 d fg f 14 g e 15 16 17 18 19 20 21 db de de fg fg g gf b eb g a a e e cf b db 22 d b e ag dc dc ed gf cb f f e b d ef 23 f fb ed e g gf
More information2011de.dvi
211 ( 4 2 1. 3 1.1............................... 3 1.2 1- -......................... 13 1.3 2-1 -................... 19 1.4 3- -......................... 29 2. 37 2.1................................ 37
More information1. 2 P 2 (x, y) 2 x y (0, 0) R 2 = {(x, y) x, y R} x, y R P = (x, y) O = (0, 0) OP ( ) OP x x, y y ( ) x v = y ( ) x 2 1 v = P = (x, y) y ( x y ) 2 (x
. P (, (0, 0 R {(,, R}, R P (, O (0, 0 OP OP, v v P (, ( (, (, { R, R} v (, (, (,, z 3 w z R 3,, z R z n R n.,..., n R n n w, t w ( z z Ke Words:. A P 3 0 B P 0 a. A P b B P 3. A π/90 B a + b c π/ 3. +
More information< A F BF8A69955C8DEC90AC8D5291CC506C CB3967B292E786C7378>
輸 / 販売元 110-0008 東京都台東区池之端 2-9-1 エッジ ビル 本社 179-0073 東京都練 区 柄 3-14-17 E-mail info@digital-biology.co.jp URL http://www.digital-biology.co.jp 製造元 BioLegend 社 /BioLegend URL http:// http://www.biolegend.com/
More information行列代数2010A
a ij i j 1) i +j i, j) ij ij 1 j a i1 a ij a i a 1 a j a ij 1) i +j 1,j 1,j +1 a i1,1 a i1,j 1 a i1,j +1 a i1, a i +1,1 a i +1.j 1 a i +1,j +1 a i +1, a 1 a,j 1 a,j +1 a, ij i j 1,j 1,j +1 ij 1) i +j a
More information_0212_68<5A66><4EBA><79D1>_<6821><4E86><FF08><30C8><30F3><30DC><306A><3057><FF09>.pdf
More information
190117_Quidel社カタログ改訂【初校】.indd
RESEARCH KITS AND REAGENTS Quidel 1979 1984 MicroVue 2016 3 Immutopics MicroVue 50 ISO 13485:2003 ELISA Quidel Specialty Products is the option for all your research, biosafety and cytotoxicity testing
More information学習の手順
NAVI 2 MAP 3 ABCD EFGH D F ABCD EFGH CD EH A ABC A BC AD ABC DBA BC//DE x 4 a //b // c x BC//DE EC AD//EF//BC x y AD DB AE EC DE//BC 5 D E AB AC BC 12cm DE 10 AP=PB=BR AQ=CQ BS CS 11 ABCD 1 C AB M BD P
More information04年度LS民法Ⅰ教材改訂版.PDF
?? A AB A B C AB A B A B A B A A B A 98 A B A B A B A B B A A B AB AB A B A BB A B A B A B A B A B A AB A B B A B AB A A C AB A C A A B A B B A B A B B A B A B B A B A B A B A B A B A B A B
More informationTOP URL 1
TOP URL http://amonphys.web.fc.com/ 3.............................. 3.............................. 4.3 4................... 5.4........................ 6.5........................ 8.6...........................7
More information000 001
all-round catalogue vol.2 000 001 002 003 AA0102 AA0201 AA0701 AA0801 artistic brushes AA0602 AB2701 AB2702 AB2703 AB2704 AA0301 AH3001 AH3011 AH3101 AH3201 AH3111 AB3201 AB3202 AB2601 AB2602 AB0701 artistic
More informationPLC HMI High flexibility Simple networking Easy to use 190 HMI 2
PLC HMI High flexibility Simple networking Easy to use 190 HMI 2 Contents 4 11 14 15 3 SIMATIC PLC190 24 S7-1200/ S7-1200 S7-1200 I/OCPU ROM SIMATIC S7-1200PLC 4 S7-1200 CPU 100Mbps HMI-PLCPC-PLCPLC16
More informationBrdU Flow Kit
BrdU FLOW KIT Kit Manual FITC -anti-brdu Antibody (Kit Component. No. 23614L) Cytofix/Cytoperm Buffer (Kit Component. No. 2090KE) Perm/Wash Buffer (10x (Kit Component. No. 2091KE) Cytoperm Plus Buffer
More information日本組織適合性学会誌第20巻2号
Major Histocompatibility Complex 2013; 20 (2): 121 129 平成 25 年度認定 HLA 検査技術者講習会テキスト HLA 1) 1) HLA HLA HLA PRA Panel reactive antibody DSA Donor specific alloantibody class subclass non-hla HLA キーワード :Human
More information1 1 n 0, 1, 2,, n n 2 a, b a n b n a, b n a b (mod n) 1 1. n = (mod 10) 2. n = (mod 9) n II Z n := {0, 1, 2,, n 1} 1.
1 1 n 0, 1, 2,, n 1 1.1 n 2 a, b a n b n a, b n a b (mod n) 1 1. n = 10 1567 237 (mod 10) 2. n = 9 1567 1826578 (mod 9) n II Z n := {0, 1, 2,, n 1} 1.2 a b a = bq + r (0 r < b) q, r q a b r 2 1. a = 456,
More information2012 A, N, Z, Q, R, C
2012 A, N, Z, Q, R, C 1 2009 9 2 2011 2 3 2012 9 1 2 2 5 3 11 4 16 5 22 6 25 7 29 8 32 1 1 1.1 3 1 1 1 1 1 1? 3 3 3 3 3 3 3 1 1, 1 1 + 1 1 1+1 2 2 1 2+1 3 2 N 1.2 N (i) 2 a b a 1 b a < b a b b a a b (ii)
More information熊本県数学問題正解
00 y O x Typed by L A TEX ε ( ) (00 ) 5 4 4 ( ) http://www.ocn.ne.jp/ oboetene/plan/. ( ) (009 ) ( ).. http://www.ocn.ne.jp/ oboetene/plan/eng.html 8 i i..................................... ( )0... (
More informationMACS機器予算申請カタログ
MACS Instruments MACSQuant automacs MultiMACS gentlemacs MACSmix TM MACSQuant 3 MACSQuant Analyzer 10 MACSQuant VYBMACSQuant X MACSQuant X Coming soon! 384 well plate Laser Channel Filter (nm) Dye or Parameter
More informationi I II I II II IC IIC I II ii 5 8 5 3 7 8 iii I 3........................... 5......................... 7........................... 4........................ 8.3......................... 33.4...................
More informationX G P G (X) G BG [X, BG] S 2 2 2 S 2 2 S 2 = { (x 1, x 2, x 3 ) R 3 x 2 1 + x 2 2 + x 2 3 = 1 } R 3 S 2 S 2 v x S 2 x x v(x) T x S 2 T x S 2 S 2 x T x S 2 = { ξ R 3 x ξ } R 3 T x S 2 S 2 x x T x S 2
More information欧州特許庁米国特許商標庁との共通特許分類 CPC (Cooperative Patent Classification) 日本パテントデータサービス ( 株 ) 国際部 2019 年 7 月 31 日 CPC 版が発効します 原文及び詳細はCPCホームページのCPC Revision
欧州特許庁米国特許商標庁との共通特許分類 CPC (Cooperative Patent Classification) 日本パテントデータサービス ( 株 ) 国際部 2019 年 7 月 31 日 CPC 2019.08 版が発効します 原文及び詳細はCPCホームページのCPC Revisions(CPCの改訂 ) をご覧ください https://www.cooperativepatentclassification.org/cpcrevisions/noticeofchanges.html
More informationA B 5 C 9 3.4 7 mm, 89 mm 7/89 = 3.4. π 3 6 π 6 6 = 6 π > 6, π > 3 : π > 3
π 9 3 7 4. π 3................................................. 3.3........................ 3.4 π.................... 4.5..................... 4 7...................... 7..................... 9 3 3. p
More information取扱説明書 -詳細版- 液晶プロジェクター CP-AW3019WNJ
B A C D E F K I M L J H G N O Q P Y CB/PB CR/PR COMPONENT VIDEO OUT RS-232C LAN RS-232C LAN LAN BE EF 03 06 00 2A D3 01 00 00 60 00 00 BE EF 03 06 00 BA D2 01 00 00 60 01 00 BE EF 03 06 00 19 D3 02 00
More informationD 24 D D D
5 Paper I.R. 2001 5 Paper HP Paper 5 3 5.1................................................... 3 5.2.................................................... 4 5.3.......................................... 6
More informationCRA3689A
AVIC-DRZ90 AVIC-DRZ80 2 3 4 5 66 7 88 9 10 10 10 11 12 13 14 15 1 1 0 OPEN ANGLE REMOTE WIDE SET UP AVIC-DRZ90 SOURCE OFF AV CONTROL MIC 2 16 17 1 2 0 0 1 AVIC-DRZ90 2 3 4 OPEN ANGLE REMOTE SOURCE OFF
More informationSB-80DX SB-80DX (Jp) Jp
SB-80DX SB-80DX (Jp) Jp 2 3 4 5 6 7 k k k k k k k k k k k k k k k k 8 k k 9 k 10 k k k k k k k 11 12 13 1 5 6 2 7 8 3 4 9 10 11 12 13 14 14 1 k 8 k 2 k 9 k 3 k 10 k 4 k 5 k 11 k 6 k 12 7 k 13 14 15 16
More information研修コーナー
l l l l l l l l l l l α α β l µ l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l
More information36 th IChO : - 3 ( ) , G O O D L U C K final 1
36 th ICh - - 5 - - : - 3 ( ) - 169 - -, - - - - - - - G D L U C K final 1 1 1.01 2 e 4.00 3 Li 6.94 4 Be 9.01 5 B 10.81 6 C 12.01 7 N 14.01 8 16.00 9 F 19.00 10 Ne 20.18 11 Na 22.99 12 Mg 24.31 Periodic
More informationBD FACSArray BD FACSArray Unlimited Possibilities BD BD FACS BD FACSArray 96 2 BD FACSCalibur 4 Count 0 100 200 300 400 500 600 96 BD Cytometric Bead Array CBA Flex Set ELISA Western Blot Propldi Ce BD
More information21 1 1 1 2 2 5 7 9 11 13 13 14 18 18 20 28 28 29 31 31 34 35 35 36 37 37 38 39 40 56 66 74 89 99 - ------ ------ -------------- ---------------- 1 10 2-2 8 5 26 ( ) 15 3 4 19 62 2,000 26 26 5 3 30 1 13
More information欧州特許庁米国特許商標庁との共通特許分類 CPC (Cooperative Patent Classification) 日本パテントデータサービス ( 株 ) 国際部 2019 年 1 月 17 日 CPC 版のプレ リリースが公開されました 原文及び詳細はCPCホームページの C
欧州特許庁米国特許商標庁との共通特許分類 CPC (Cooperative Patent Classification) 日本パテントデータサービス ( 株 ) 国際部 2019 年 1 月 17 日 CPC 2019.02 版のプレ リリースが公開されました 原文及び詳細はCPCホームページの CPC Revisions(CPCの改訂 ) 内のPre-releaseをご覧ください http://www.cooperativepatentclassification.org/cpcrevisions/prereleases.html
More informationA(6, 13) B(1, 1) 65 y C 2 A(2, 1) B( 3, 2) C 66 x + 2y 1 = 0 2 A(1, 1) B(3, 0) P 67 3 A(3, 3) B(1, 2) C(4, 0) (1) ABC G (2) 3 A B C P 6
1 1 1.1 64 A6, 1) B1, 1) 65 C A, 1) B, ) C 66 + 1 = 0 A1, 1) B, 0) P 67 A, ) B1, ) C4, 0) 1) ABC G ) A B C P 64 A 1, 1) B, ) AB AB = 1) + 1) A 1, 1) 1 B, ) 1 65 66 65 C0, k) 66 1 p, p) 1 1 A B AB A 67
More informationR R 16 ( 3 )
(017 ) 9 4 7 ( ) ( 3 ) ( 010 ) 1 (P3) 1 11 (P4) 1 1 (P4) 1 (P15) 1 (P16) (P0) 3 (P18) 3 4 (P3) 4 3 4 31 1 5 3 5 4 6 5 9 51 9 5 9 6 9 61 9 6 α β 9 63 û 11 64 R 1 65 13 66 14 7 14 71 15 7 R R 16 http://wwwecoosaka-uacjp/~tazak/class/017
More informationuntitled
5 28 EAR CCLECCN ECCN 1. 2. 3. 4. 5.EAR page 1 of 28 WWW.Agilent.co.jp -> Q&A ECCN 10020A 10070A 10070B 10070C 10071A 10071B 10072A 10073A 10073B 10073C 10074A 10074B 10074C 10076A 10229A 10240B 10430A
More information国試過去問集.PDF
I 89 16 3 130 ab c AMPcAMP a 1 --- b c --- 2 --- --- 3 --- --- 4 --- --- 5 --- --- camp camp Ca 2+ β1 camp A camp camp A β1 p.156 β p.146 b. p.157 p135 (ANP) p157 c PDE-III p.157 p.157, 183 PDE C Ca PDE-III
More information05秋案内.indd
1 2 3 4 5 6 7 R01a U01a Q01a L01a M01b - M03b Y01a R02a U02a Q02a L02a M04b - M06b Y02a R03a U03a Q03a L03a M08a Y03a R04a U04a Q04a L04a M09a Y04a A01a L05b, L07b, R05a U05a Q05a M10a Y05b - Y07b L08b
More information_19MY_E-PACE
JAGUAR E- PACE PECIFICATION AND PRICE GUIDE ELECT PACK セレクトパック セレクトパック セレクトパック 066AC 129AA 070AV 070BA 017TB 119,000 80,000 087AU 011CB 064GK 300CF 064Q HE セレクトパック セレクトパック 119,000 119,000 119,000 99,000
More informationa (a + ), a + a > (a + ), a + 4 a < a 4 a,,, y y = + a y = + a, y = a y = ( + a) ( x) + ( a) x, x y,y a y y y ( + a : a ) ( a : a > ) y = (a + ) y = a
[] a x f(x) = ( + a)( x) + ( a)x f(x) = ( a + ) x + a + () x f(x) a a + a > a + () x f(x) a (a + ) a x 4 f (x) = ( + a) ( x) + ( a) x = ( a + a) x + a + = ( a + ) x + a +, () a + a f(x) f(x) = f() = a
More informationContents 4 06 IP2 41 Thermo Scientific Nalgene Nalgene
Nalgene & Packaging plastic Bottles & Vials Contents 4 06 IP2 41 Thermo Scientific Nalgene 5 07 42 8 08 43 9 09 45 11 10 46 Nalgene 12 11 50 13 12 53 01 20 13 61 02 28 14 64 03 33 15 66 04 37 16 / 67 05
More informationZ 2 10Z MPa MPa MPa MPa 1.5MPa s s s JIS 6g/6H SD SD/B LB LS
3 03 0.01MPa 0.1MPa 0.1MPa 0.01MPa 1.MPa 0s 0s 0s JIS g/h SDSD/BLB LS0 F FBTT/BTB TB/BCUCU/B SDLCFTT/B TCTC/BDBD SDSD/BLB LS0 F FBTT/BTB TB/BCUCU/B SDLBFTT/B SKSPLK LP FKFP SKSPLK LP FKFP TKTPDPBDBP TKTPDPBDBP
More informationLCR e ix LC AM m k x m x x > 0 x < 0 F x > 0 x < 0 F = k x (k > 0) k x = x(t)
338 7 7.3 LCR 2.4.3 e ix LC AM 7.3.1 7.3.1.1 m k x m x x > 0 x < 0 F x > 0 x < 0 F = k x k > 0 k 5.3.1.1 x = xt 7.3 339 m 2 x t 2 = k x 2 x t 2 = ω 2 0 x ω0 = k m ω 0 1.4.4.3 2 +α 14.9.3.1 5.3.2.1 2 x
More information免疫Ⅱ
100 100 100 1990 127 DNA DNA DNA DNA hybridization DNA RNA DNA DNA 128 12 µδγαε 129 300 1,200 500 50012 4 24,000 1,20024,000 2.910 7 10 8 rejection major histocompatibility complex MHC MHC MHC 130 MHC
More informationDVIOUT-HYOU
() P. () AB () AB ³ ³, BA, BA ³ ³ P. A B B A IA (B B)A B (BA) B A ³, A ³ ³ B ³ ³ x z ³ A AA w ³ AA ³ x z ³ x + z +w ³ w x + z +w ½ x + ½ z +w x + z +w x,,z,w ³ A ³ AA I x,, z, w ³ A ³ ³ + + A ³ A A P.
More information空き容量一覧表(154kV以上)
1/3 A. 電気所 ( 発電所, 変電所, 配電塔 ) における変圧器の空き容量 覧 < 留意事項 > (1) 空容量は 安であり 系統接続の前には 接続検討のお申込みによる詳細検討が必要となります その結果 空容量が変更となる場合があります (2) 熱容量を考慮した空き容量を記載しております その他の要因 ( や系統安定度など ) で連系制約が発 する場合があります (3) 表 は 既に空容量がないため
More information2/8 一次二次当該 42 AX 変圧器 なし 43 AY 変圧器 なし 44 BA 変圧器 なし 45 BB 変圧器 なし 46 BC 変圧器 なし
1/8 A. 電気所 ( 発電所, 変電所, 配電塔 ) における変圧器の空き容量一覧 < 留意事項 > (1) 空容量は目安であり 系統接続の前には 接続検討のお申込みによる詳細検討が必要となります その結果 空容量が変更となる場合があります (2) 特に記載のない限り 熱容量を考慮した空き容量を記載しております その他の要因 ( や系統安定度など ) で連系制約が発生する場合があります (3)
More information70 : 20 : A B (20 ) (30 ) 50 1
70 : 0 : A B (0 ) (30 ) 50 1 1 4 1.1................................................ 5 1. A............................................... 6 1.3 B............................................... 7 8.1 A...............................................
More informationRIDGID_Catalog_2016_web.pdf
K-1/K-3/K-6 115 K-5 116 116 117 K-26 117 K-25 117 K-30 118 K-45AF 119 120 K-40AF 121 K-400 123 K-3800 125 K-6200 127 K-50 129 K-1500 131 KJ-2200 133 135 114 46683 K-1 K-1 K-1 46683 K-1 59787 K-3 59797
More informationNikon SB-800 使用説明書
Jp SB-800 2! $ ' $ % & " " " " " 3 ' ( # # # # # # & " " "! " " # ' # $ # " " " " " 4 " " " " ( # " " " " 5 6 " " " " # # # ( $ " " " 7 " " " " " " " # # # ( $ ' 8 9 k k k k k k k k k k u 10 k k k k k
More informationHITACHI 液晶プロジェクター CP-AX3505J/CP-AW3005J 取扱説明書 -詳細版- 【技術情報編】
B A C E D 1 3 5 7 9 11 13 15 17 19 2 4 6 8 10 12 14 16 18 H G I F J M N L K Y CB/PB CR/PR COMPONENT VIDEO OUT RS-232C LAN RS-232C LAN LAN BE EF 03 06 00 2A D3 01 00 00 60 00 00 BE EF 03 06 00 BA D2 01
More information1 1 H Li Be Na M g B A l C S i N P O S F He N Cl A e K Ca S c T i V C Mn Fe Co Ni Cu Zn Ga Ge As Se B K Rb S Y Z Nb Mo Tc Ru Rh Pd Ag Cd In Sn Sb T e
No. 1 1 1 H Li Be Na M g B A l C S i N P O S F He N Cl A e K Ca S c T i V C Mn Fe Co Ni Cu Zn Ga Ge As Se B K Rb S Y Z Nb Mo Tc Ru Rh Pd Ag Cd In Sn Sb T e I X e Cs Ba F Ra Hf Ta W Re Os I Rf Db Sg Bh
More informationuntitled
0. =. =. (999). 3(983). (980). (985). (966). 3. := :=. A A. A A. := := 4 5 A B A B A B. A = B A B A B B A. A B A B, A B, B. AP { A, P } = { : A, P } = { A P }. A = {0, }, A, {0, }, {0}, {}, A {0}, {}.
More information‚å™J‚å−w“LŁñ›ÄP1-7_7/4
2006 167 FFFFFFFFF FFFFFFFFF 2 3 4 5 6 7 8 9 d ca 10 c f e 11 e g e 12 d b 13 f bf 14 15 16 17 b c d cc bc e ef gf gf dc dc bc f f cd bf e df bd f bf c C d E c e 18 19 bc b b f 20 d d e d e bf ec d e ef
More informationFCシリンダ
CAT. No. KS-570-01 C ujikura cylinder INDEX Page CS - - -22 CS - -3 - CD - -3 - CS -40-0 -4 CD -40-0 -4 CS - -20-3 CD - -20-3 CL-400 VCS CDR -400 1 ujikura Cylinders 2 3 4 C 0 3 0.0.7 00 CD 0 4 S0 P CS
More informationh1-4_cs5.5.indd
SIMATIC HMI SIMATIC HMI SIMATIC HMI Comfort Panel All-in-One SIMATIC Comfort Panel all-in-one 4 22 1677 0 100% IP65 CEULKCRCMATEX HMI VB HMI ATEX 4 12 SIMATIC HMI Basic Panel 2 nd Generation SIMATIC Basic
More informationA G A G A G 4 1 1 2 3 4 5 6 7 110119118 b A G C G 4 1 7 * * G A C b a HIKJ K J L f B c g 9 K c d g e 7 G 7 1 G 1 aa g g g c L M G L H G G 4 aa c c A a c CB B C A G f A G f G 9 8 1 2
More information20 6 4 1 4 1.1 1.................................... 4 1.1.1.................................... 4 1.1.2 1................................ 5 1.2................................... 7 1.2.1....................................
More information0406_total.pdf
59 7 7.1 σ-ω σ-ω σ ω σ = σ(r), ω µ = δ µ,0 ω(r) (6-4) (iγ µ µ m U(r) γ 0 V (r))ψ(x) = 0 (7-1) U(r) = g σ σ(r), V (r) = g ω ω(r) σ(r) ω(r) (6-3) ( 2 + m 2 σ)σ(r) = g σ ψψ (7-2) ( 2 + m 2 ω)ω(r) = g ω ψγ
More informationO E ( ) A a A A(a) O ( ) (1) O O () 467
1 1.0 16 1 ( 1 1 ) 1 466 1.1 1.1.1 4 O E ( ) A a A A(a) O ( ) (1) O O () 467 ( ) A(a) O A 0 a x ( ) A(3), B( ), C 1, D( 5) DB C A x 5 4 3 1 0 1 3 4 5 16 A(1), B( 3) A(a) B(b) d ( ) A(a) B(b) d AB d = d(a,
More information™…{,
16:30-17:40 1-36 1-37 1-38 1-39 1-40 1-41 1-42 33 10:00-11:10 1-43 1-44 1-45 1-46 1-47 1-48 1-49 12:00-12:50 LS4 34 16:30-17:40 1-50 1-51 1-52 1-53 1-54 1-55 1-56 35 16:30-17:40 1-57 1-58 1-59 1-60 1-61
More informationA24656JP_EVOS_Onstage_Incubator_cover.indd
フローサイトメトリープロトコル集 イムノフェノタイピング アポトーシス 細胞周期 作成日 2017 年 5 月 Version 1.0 研究目的でのみ使用できます 診断には使用できません A. 細胞表面マーカーの染色 蛍光標識した細胞表面マーカーとフローサイトメトリー解析を組み合わせることにより 分化や発生のステージ また細胞機能に基づいた細胞集団サブセットの同定が可能になります これらの表面マーカーには様々なタイプまたは機能があり
More information